论文部分内容阅读
目的:研究核因子E2相关因子2(Nrf2)、O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)在不同病理级别人脑胶质瘤中的阳性表达情况,分析其临床预后与病理分级之间的关系。方法:收集76例脑胶质瘤组织及14例正常脑组织中作为研究对象,采用免疫组织化学(SP法)分析Nrf2及MGMT表达情况,并分析其与临床预后之间的相关性。结果:Nrf2在胶质瘤组织中阳性表达率较正常组增高,其阳性表达强度与肿瘤病理分级之间呈正相关关系(Z=2.843,P<0.01),Nrf2与MGMT的阳性表达强度呈正相关(r=0.683,P<0.01);Nrf2表达强度中度或强阳性者3年预后生存率明显低于Nrf2表达阴性或者弱阳性(-~+),P<0.01。结论:胶质瘤组中的Nrf2的阳性表达增高,且与患者的预后生存率负相关。Nrf2和MGMT可作为胶质瘤病理分级及临床预后判断的指标。
Objective: To investigate the positive expression of nuclear factor E2 (Nrf2) and O6-methylguanine-DNA methyltransferase (MGMT) in human gliomas of different pathological grades, and to analyze the clinical prognosis and pathological grading The relationship between. Methods: Totally 76 glioma tissues and 14 normal brain tissues were collected. The expression of Nrf2 and MGMT were analyzed by immunohistochemistry (SP method), and their correlations with clinical prognosis were analyzed. Results: The positive expression rate of Nrf2 in glioma tissue was higher than that in normal group. The positive expression rate of Nrf2 was positively correlated with tumor grade (Z = 2.843, P <0.01), and positive correlation between Nrf2 and MGMT r = 0.683, P <0.01). The 3-year survival rate of moderate or strong positive expression of Nrf2 was significantly lower than that of Nrf2 negative or weak positive (P <0.01). Conclusion: The positive expression of Nrf2 in glioma group is increased, and negatively correlated with the prognosis of patients. Nrf2 and MGMT can be used as glioma pathological grading and clinical prognostic indicators.